 |
1 Disease |  |
67 Trials |
|
67 Trials |  |
1555 News |  |
| «12...24252627282930313233343536» |
- |||| Libtayo (cemiplimab) / Sanofi, Regeneron, Enbrel (etanercept) / Pfizer, Amgen
I've had a durable CR following chemo resistance using combined Cemiplimab and anti-TNF etanercept. Anti-TNF agents may also be considerations in select situations. #cancerimmunotherapy #immunooncology @HaanenJohn (Twitter) - Jun 13, 2020
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date, Metastases: Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 11, 2020
P2, N=21, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
- | Libtayo (cemiplimab) / Regeneron
Trial completion date, Trial primary completion date: Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART (clinicaltrials.gov) - Jun 11, 2020
P1/2, N=45, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024 Trial completion date: Dec 2021 --> Aug 2020 | Trial primary completion date: Sep 2021 --> Aug 2020
- | Libtayo (cemiplimab-rwlc) / Regeneron
New P1 trial, Surgery: Winship4851-19: Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer (clinicaltrials.gov) - Jun 11, 2020
P1, N=20, Active, not recruiting, Sponsor: Emory University
- || Libtayo (cemiplimab) / Sanofi, Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal: Medical treatment of advanced cutaneous squamous-cell carcinoma. (Pubmed Central) - Jun 8, 2020
EGFR inhibitors are therefore more suitable for multimorbid and/or frail elderly patients. By combining EGFR inhibitors with local therapy such as surgery or radiotherapy, response rates and duration of response may be improved.
- | Libtayo (cemiplimab) / Sanofi, Regeneron, fianlimab (REGN3767) / Regeneron, Sanofi
Preclinical, Journal, Combination therapy: Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice. (Pubmed Central) - Jun 4, 2020
In these humanized mice, treatment with cemiplimab and REGN3767 showed increased efficacy in a mouse tumor model and enhanced the secretion of proinflammatory cytokines by tumor-specific T cells. The favorable pharmacokinetics and toxicology of REGN3767 in non-human primates, together with enhancement of anti-tumor efficacy of anti-PD-1 Ab in preclinical tumor models, supports its clinical development.
- | Libtayo (cemiplimab) / Sanofi, Regeneron, Keytruda (pembrolizumab) / Merck (MSD), Erivedge (vismodegib) / Roche
Review, Journal: The Landmark Series: Non-melanoma Skin Cancers. (Pubmed Central) - Jun 4, 2020
These trials have not only changed the landscape for patients with metastatic disease but also notably for patients with locally advanced disease that is either unresectable or resectable with high morbidity. Additional mention is made for the clinical trial that led to FDA approval of cemiplimab for advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1), which is already changing practice patterns, but for which longer-term data are still needed.
- |||| Libtayo (cemiplimab) / Sanofi, Regeneron
Looks like $SNY reckons Libtayo's best chance to compete in 1L NSCLC is in ≥50% PD-L1 expr. Meanwhile, CEACAM5 is the combo hope. (Twitter) - Jun 2, 2020
- | Libtayo (cemiplimab) / Sanofi, Regeneron
Biomarker, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker: Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. (Pubmed Central) - May 23, 2020
Additional mention is made for the clinical trial that led to FDA approval of cemiplimab for advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1), which is already changing practice patterns, but for which longer-term data are still needed. CNAs in the 21-27 bands of chromosome arm 3q, a region that includes PIK3CA, ETV5 and BCL6, may represent predictors of response to ICI and may be candidates for drug targeting in combination or sequence with ICI agents.
- || Libtayo (cemiplimab-rwlc) / Regeneron, odronextamab (REGN1979) / Regeneron
Enrollment closed: CLIO-1: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (clinicaltrials.gov) - May 22, 2020
P1, N=172, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
CNAs in the 21-27 bands of chromosome arm 3q, a region that includes PIK3CA, ETV5 and BCL6, may represent predictors of response to ICI and may be candidates for drug targeting in combination or sequence with ICI agents. Recruiting --> Active, not recruiting
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] IMMUNE CHECKPOINT INHIBITOR THERAPY IN PATIENTS WITH PREEXISTING SARCOIDOSIS (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_4077;
Patients with a remote history of stable sarcoidosis at the time of ICI therapy infrequently develop a flare of their sarcoidosis. The risk of flares in patients with active sarcoidosis requiring immunosuppression at the time of ICI initiation is unknown.
- |||| ISA101 / ISA Pharma
New P2 trial, Metastases: ProcemISA: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC (clinicaltrials.gov) - May 21, 2020
P2, N=86, Not yet recruiting, Sponsor: ISA Pharmaceuticals
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System. (Pubmed Central) - May 21, 2020
The risk of flares in patients with active sarcoidosis requiring immunosuppression at the time of ICI initiation is unknown. This case suggests that anti-PD-1 therapy with pembrolizumab may represent an effective and well-tolerated treatment for patients with metastatic spindle cell squamous cell carcinoma including patients with metastatic disease to the central nervous system.
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial completion date, Trial primary completion date, Metastases: EMPOWER-CSCC-1 : Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - May 20, 2020
P2, N=433, Recruiting, Sponsor: Regeneron Pharmaceuticals
This case suggests that anti-PD-1 therapy with pembrolizumab may represent an effective and well-tolerated treatment for patients with metastatic spindle cell squamous cell carcinoma including patients with metastatic disease to the central nervous system. N=266 --> 433 | Trial completion date: Aug 2021 --> Dec 2025 | Trial primary completion date: Feb 2020 --> Oct 2025
- Opdivo (nivolumab) / Ono Pharma, BMS
Prediction and comparison of PD-1 receptor occupancy in the tumor after treatment with immune checkpoint inhibitors (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_236;
Moreover, predictions of PD-1 occupancy in the tumor may be used for informed dose selection or explanation of clinical trial results. This approach can be expanded for mAbs targeting other receptors including bi- or multispecific antibodies with different structures and properties.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Predictors of Immune Checkpoint Inhibitor Associated Cardiotoxicity () - May 13, 2020 - Abstract #QCOR2020QCOR_213;
One of the patients who developed myocarditis received pembrolizumab, one nivolumab and one cemiplimab (all PD-1 inhibitors). A history of heart failure is associated with an increased odds of developing cardiotoxicity after ICI exposure while prior beta blocker exposure appears to be protective.
- || SAR441000 / Sanofi, BioNTech
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 12, 2020
P1, N=264, Recruiting, Sponsor: Sanofi
A history of heart failure is associated with an increased odds of developing cardiotoxicity after ICI exposure while prior beta blocker exposure appears to be protective. Trial completion date: Dec 2021 --> Feb 2024 | Trial primary completion date: Aug 2021 --> Oct 2023
- | New P1 trial, Checkpoint inhibition, Checkpoint block, Metastases: Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (clinicaltrials.gov) - May 12, 2020
P1, N=16, Not yet recruiting, Sponsor: University of Southern California
- ||| Voyager-V1 / Vyriad
Enrollment open, Combination therapy: Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients (clinicaltrials.gov) - May 11, 2020
P2, N=152, Recruiting, Sponsor: Vyriad, Inc.
Trial completion date: Dec 2021 --> Feb 2024 | Trial primary completion date: Aug 2021 --> Oct 2023 Not yet recruiting --> Recruiting
- |||| BNT112 / BioNTech
New P1/2 trial, Combination therapy, Monotherapy: PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (clinicaltrials.gov) - May 10, 2020
P1/2, N=80, Recruiting, Sponsor: Biontech RNA Pharmaceuticals GmbH
- || Libtayo (cemiplimab) / Sanofi, Regeneron
Battling low expectations and goliath rivals, Regeneron/Sanofi continue to pursue blockbuster status for Libtayo https://t.co/kdsT5R2kxr (Twitter) - May 4, 2020
- |||| Libtayo (cemiplimab) / Regeneron
New P2 trial: Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma (clinicaltrials.gov) - May 3, 2020
P2, N=100, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- || Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Trial completion date, Trial primary completion date, Combination therapy, Metastases: R3767-ONC-1613: Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers (clinicaltrials.gov) - Apr 30, 2020
P1, N=669, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Oct 2021 --> Sep 2023 | Trial primary completion date: Mar 2021 --> Feb 2023
- Libtayo (cemiplimab) / Sanofi, Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Safety and efficacy of checkpoint inhibitors in solid organ transplant recipients with cutaneous squamous cell carcinoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5703;
Short-term efficacy appears promising and prospective studies are warranted. *Ongoing treatment Research Funding: None
- Libtayo (cemiplimab) / Sanofi, Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Assessing the value of cemiplimab for adults with advanced cutaneous squamous cell carcinoma (CSCC): A cost-effectiveness analysis. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5106;
P2
Research Funding: Regeneron Pharmaceuticals, Inc. and Sanofi
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Immune-checkpoint inhibitors among privately insured cancer patients: Utilization pattern and out-of-pocket cost. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4961;
Although more than 50% of pts had $0 OOP, possibly due to the out-of-pocket max provision in private insurance, pts with HD plans are especially susceptible to high financial burden of ICIs. Research Funding: None
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Exclusion rates of patients living with HIV from cancer immunotherapy clinical trials. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4744;
Despite ASCO and Friends of Cancer Research recommendations to include patients with HIV in cancer clinical trials, the vast majority of immunotherapy clinical trials in 2019 exclude patients with cancer and HIV. Research Funding: None
- Libtayo (cemiplimab) / Sanofi, Regeneron, docetaxel / Generic mfg.
[VIRTUAL] Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4446;
P2
Taken together these show the feasibility of SS-RNA-seq on PC metastatic lesions and provide initial support for the hypothesis that ADT induces complex immunological changes in the tumor microenvironment (TME) in metastatic prostate tumors. Research Funding: Conquer Cancer Foundation of the American Society of Clinical Oncology, Other Government Agency
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Predictors of immunotherapy (IO) response and subsequent tyrosine kinase inhibitor (TKI) response in hepatocellular carcinoma (HCC). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4116;
Abnormal TSH during IO treatment tended toward improved mOS. In addition data strongly indicates subsequent TKI therapy improves patient outcomes after IO.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Incidence and risk of colitis with programmed death-1 versus programmed death-ligand 1 inhibitors for the treatment of cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3462;
Our study showed that PD-1 inhibitors have higher risk of colitis than PD-L1 inhibitors. Research Funding: None
- Libtayo (cemiplimab) / Sanofi, Regeneron
[VIRTUAL] Controlled IL-12 in combination with cemiplimab-rwlc in adult subjects with recurrent glioblastoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3337;
- AST-008 / Exicure
[VIRTUAL] AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC). (Poster Board 228) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1434;
P1b/2
The planned phase II enrollment is 58 pts across about 15 US-based sites. Research Funding: Exicure Inc
- Voyager-V1 / Vyriad, Profectus, Libtayo (cemiplimab) / Sanofi, Regeneron
[VIRTUAL] Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma. (Poster Board 225) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1431;
Cohorts will be expanded based on signal of activity. Research Funding: Vyriad Inc
- Voyager-V1 / Vyriad, Profectus, Bavencio (avelumab) / EMD Serono, Pfizer, Libtayo (cemiplimab) / Sanofi, Regeneron
[VIRTUAL] Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors. (Poster Board 154) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1365;
P1
VV1 is safe for caregivers, with no viral shedding. Part 3 of this study will now treat CRC patients with VV1 in combination with a checkpoint inhibitor (avelumab).
- Libtayo (cemiplimab) / Sanofi, Regeneron
[VIRTUAL] A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer. (Poster Board 173) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1165;
P1/2
This study is currently open to enrollment. Research Funding: Regeneron Pharmaceuticals Inc.
- |||| Libtayo (cemiplimab) / Sanofi, Regeneron
The 6th IO drug in lung cancer to show survival benefit! Looking forward to seeing the full data! #LCSM Cemiplimab Improves Survival in Frontline PD-L1–High NSCLC https://t.co/Mu3ll9Oca5 via @onclive (Twitter) - Apr 28, 2020
- ||||| Libtayo (cemiplimab) / Sanofi, Regeneron
Clinical: Yet another PD-1 agent with positive Phase 3 data(cemiplimab) in First-Line Advanced Non-small Cell Lung Cancer (PD-L1 50%). Trial stopped Early Due to Improvement in Overall Survival. https://t.co/Zm0KRlD3PV (Twitter) - Apr 27, 2020
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed, Metastases: R2810-ONC-1620: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy (clinicaltrials.gov) - Apr 24, 2020
P2, N=137, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Research Funding: Regeneron Pharmaceuticals Inc. Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS
Retrospective data, Journal: Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials. (Pubmed Central) - Apr 23, 2020
No statistically significant association of liver metastases with the efficacy of treatments with PD-1 or PD-L1 inhibitors in the treatment of advanced or metastatic cancer was found in the stratified analyses. Moreover, future studies about the safety of the PD-1 or PD-L1 inhibitors in patients with or without liver metastases are warranted.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Discovery of New Immune Checkpoints: Family Grows Up. (Pubmed Central) - Apr 21, 2020
Moreover, clinicians observed some cases switching to progression after achieving partial or complete response, indicating treatment failure or drug resistance. So people begin looking for the next generation of immune checkpoint members.
- | SAR439459 / Sanofi
Trial completion date, Combination therapy, Monotherapy, Metastases: A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 20, 2020
P1, N=225, Recruiting, Sponsor: Sanofi
So people begin looking for the next generation of immune checkpoint members. Trial completion date: Aug 2022 --> May 2022
- || Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Trial completion, PD(L)-1 Biomarker, IO biomarker, Immunomodulating, Biopsy: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Apr 20, 2020
P1, N=47, Completed, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Aug 2022 --> May 2022 Active, not recruiting --> Completed
- || Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 19, 2020
P2, N=76, Recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Apr 2025 --> Dec 2024 | Trial primary completion date: May 2021 --> Jan 2021
- | Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal, PD(L)-1 Biomarker, IO Biomarker: Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. (Pubmed Central) - Apr 17, 2020
Recently, we demonstrated that the down-regulation or inhibition of glycogen synthase kinase 3 (GSK-3) down-regulates PD-1 expression in infectious diseases and cancer (Taylor et al., 2016 Immunity 44, 274-86; 2018 Cancer Research 78, 706-717; Krueger and Rudd 2018 Immunity 46, 529-531). In this Review, we outline the use of small molecule inhibitors (SMIs) that target intracellular pathways for co-receptor blockade in cancer immunotherapy.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date, IO biomarker, Metastases: EMPOWER-lung 4: A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer (clinicaltrials.gov) - Apr 14, 2020
P2, N=28, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
In this Review, we outline the use of small molecule inhibitors (SMIs) that target intracellular pathways for co-receptor blockade in cancer immunotherapy. Trial completion date: Apr 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Aug 2021
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: EMPOWER-lung 1: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 14, 2020
P3, N=712, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Apr 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Aug 2021 Recruiting --> Active, not recruiting | Trial completion date: Feb 2023 --> Nov 2022 | Trial primary completion date: Feb 2023 --> Nov 2022
- Libtayo (cemiplimab) / Sanofi, Regeneron, Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
[VIRTUAL] A phase Ib study of recombinant vaccinia virus in combination with immune checkpoint inhibition (ICI) in advanced renal cell carcinoma (RCC) (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_121;
P1b
Further investigation is on-going with additional patients in stage 2 of expansion cohort C and another cohort with IT Pexa-Vec + cemiplimab. A newly added Cohort D of patients who progressed on previous immune checkpoint inhibition is to be opened soon.
- | Libtayo (cemiplimab) / Sanofi, Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Journal: Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? (Pubmed Central) - Apr 10, 2020
A newly added Cohort D of patients who progressed on previous immune checkpoint inhibition is to be opened soon. The present study reviews the current definition of advanced cSCC and discusses the new systemic approaches, including checkpoint inhibitors.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial suspension, Metastases: Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer (clinicaltrials.gov) - Apr 8, 2020
P2, N=36, Suspended, Sponsor: Medical College of Wisconsin
The present study reviews the current definition of advanced cSCC and discusses the new systemic approaches, including checkpoint inhibitors. Not yet recruiting --> Suspended
- || Libtayo (cemiplimab-rwlc) / Regeneron
New P1 trial, Metastases: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Apr 7, 2020
P1, N=12, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute